Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2026 Top Employers Survey for the twelfth consecutive year.
Moderna was recognized for its corporate image, leadership and direction, and work culture, reflecting its reputation for innovation and quality research, commitment to continuous improvement, and collaborative, data-driven environment.
"At Moderna, we have always believed that the best science happens when talented people are given the opportunity to tackle important problems and make an impact," said CEO Stéphane Bancel.
"To be recognized by Science for twelve consecutive years is a testament to the thousands of people who have helped build and evolve this company. What continues to unite us is a shared determination to advance mRNA science and translate that work into meaningful advances for patients."
In 2026, Moderna received approval for its fourth and fifth products. mCOMBRIAX®, the Company's mRNA combination vaccine for the prevention of influenza disease and COVID-19 caused by SARS-CoV-2 was granted marketing authorization in the European Union in April 2026. mFLUSIVA®, a new vaccine against seasonal influenza was approved by the U.S. Food and Drug Administration in August 2026.
MRNA shares sank $4.61, or 2.3%, to $198.02.
